Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17753536 | 0.93 | CHRM2 (0.54) | CHRM2MEN1KMT2ASCN8AMAPK1 | |
| SCHEMBL8273971 | 0.90 | TDP1 (0.58) | TP53CHRM2MEN1KMT2ASCN8A | |
| SCHEMBL13705507 | 0.84 | TP53 (0.53) | TP53MEN1KMT2ACNR1GPR55 | |
| SCHEMBL17339767 | 0.84 | SIGMAR1 (0.67) | MEN1KMT2AHTTSIGMAR1HTR1A | |
| SCHEMBL17339769 | 0.83 | MEN1 (0.62) | TP53CHRM2MEN1KMT2ASCN8A | |
| SCHEMBL13705509 | 0.81 | TDP1 (0.62) | TP53MEN1KMT2ACNR1GPR55 | |
| SCHEMBL17340063 | 0.81 | SLC6A2 (0.56) | MEN1KMT2AHTTSIGMAR1HTR1A | |
| SCHEMBL14160236 | 0.78 | SCN1A (0.55) | CHRM2MEN1KMT2ALMNAMAPK1 | |
| SCHEMBL17753539 | 0.75 | SIGMAR1 (0.77) | HTTSIGMAR1HTR1A | |
| SCHEMBL14160114 | 0.75 | SCN1A (0.55) | CHRM2MEN1KMT2ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160136115-A1 | T TYPE CALCIUM CHANNEL INHIBITORS | UNIVERSITY OF VIRGINIA | 2016-05-19 | — | — | US | disclosed |
| US-9212127-B2 | T type calcium channel inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212127-B2 | T type calcium channel inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136115-A1 | T TYPE CALCIUM CHANNEL INHIBITORS | CACNA1H, CACNA1I, CACNA1G | TP53 3976/4885CHRM2 1067/4885MEN1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.